{
    "key_points": [
        "Two mRNA COVID-19 vaccines have shown approximately 95% effectiveness in preventing the disease in adults.",
        "The FDA emphasizes the importance of following the authorized dosing schedules for COVID-19 vaccines.",
        "Discussions about altering vaccine dosing schedules or mixing vaccines are considered premature without solid evidence.",
        "Changing the authorized dosing schedule without adequate data may pose a significant risk to public health.",
        "The Pfizer-BioNTech vaccine requires a 21-day interval between doses, while the Moderna vaccine requires 28 days.",
        "Misinterpretation of data regarding a single dose's effectiveness can lead to unwarranted assumptions about protection.",
        "There's concern that altering dose regimens without understanding protection depth and duration could be harmful.",
        "The FDA stresses that decisions will continue to be based on data and science.",
        "Healthcare providers are strongly recommended to follow the FDA-authorized dosing schedule.",
        "The FDA's role includes assuring the safety and effectiveness of drugs, vaccines, and other biological products."
    ],
    "spokespersons": [],
    "article_type": "government agency statement",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}